

<https://helda.helsinki.fi>

Cerebral autoregulation after aneurysmal subarachnoid haemorrhage. A preliminary study comparing dexmedetomidine to propofol and/or midazolam

Kallioinen, Minna

2020-10

Kallioinen , M , Posti , J P , Rahi , M , Sharma , D , Katila , A , Grönlund , J , Vahlberg , T , Frantzén , J , Olkkola , K T , Saari , T I & Takala , R 2020 , ' Cerebral autoregulation after aneurysmal subarachnoid haemorrhage. A preliminary study comparing dexmedetomidine to propofol and/or midazolam ' , Acta Anaesthesiologica Scandinavica , vol. 64 , no. 9 , pp. 1278-1286 . <https://doi.org/10.1111/aas.13663>

<http://hdl.handle.net/10138/332074>

<https://doi.org/10.1111/aas.13663>

unspecified

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

DR MINNA KALLIOINEN (Orcid ID : 0000-0002-6505-1496)

PROFESSOR TEIJO I SAARI (Orcid ID : 0000-0003-1225-4561)

DR RIIKKA SK TAKALA (Orcid ID : 0000-0001-6342-0043)

Article type : Clinical investigation

CEREBRAL AUTOREGULATION AFTER ANEURYSMAL SUBARACHNOID HAEMORRHAGE. A PRELIMINARY STUDY COMPARING DEXMEDETOMIDINE TO PROPOFOL AND/OR MIDAZOLAM.

Minna Kallioinen^{1,2}, Jussi P. Posti^{3,4}, Melissa Rahi³, Deepak Sharma⁵, Ari Katila¹, Juha Grönlund¹,
Tero Vahlberg⁶, Janek Frantzén³, Klaus T. Olkkola⁷, Teijo I. Saari^{2,1}, Riikka Takala^{1,2}

Names of Departments and Institutions:

- 1) Division of Perioperative Services, Intensive Care Medicine and Pain Management, Turku University Hospital and University of Turku, Finland
- 2) Department of Anaesthesiology and Intensive Care, University of Turku, Finland
- 3) Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital and University of Turku, Finland
- 4) Turku Brain Injury Centre, Turku University Hospital, Finland
- 5) Department of Anaesthesiology & Pain Medicine, University of Washington, Seattle, WA, USA.
- 6) Department of Clinical Medicine, Biostatistics, University of Turku and Turku University Hospital, Finland
- 7) Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and HUS Helsinki University Hospital, Finland

Short title: Dexmedetomidine in aSAH patients

Word count: 2991

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/aas.13663](https://doi.org/10.1111/aas.13663)

This article is protected by copyright. All rights reserved

Conflicts of interest: Dr. Takala is a minor stock owner of Orion Corporation and Oriola. Dr. Takala has received speaker's fee from Orion Corporation, Abbott, Baxter, Fresenius Kabi and UCB and travel grants from Steripolar and Pfizer. Dr. Posti has received speaker's fees from Orion Corporation and Finnish Medical Association and a travel grant from Stryker Corporation. Dr. Grönlund has received speaker's fees from Orion Corporation. Dr. Saari has received speaker's fees from Orion Corporation. Dr. Frantzén has received speaker's fees from Orion Corporation and Teva Pharmaceutical Industries and a travel grant from Abbot.

Corresponding author: Dr Minna Kallioinen, minna.kallioinen@tyks.fi, mijoka@utu.fi, +358 2 313 5064, Perioperative Services, Intensive Care Medicine and Pain Management, Turku University Hospital, Turku, Finland

ABSTRACT

Background: Cerebral autoregulation is often impaired after aneurysmal subarachnoid haemorrhage (aSAH). Dexmedetomidine is being increasingly used, but its effects on cerebral autoregulation in patients with aSAH have not been studied before. Dexmedetomidine could be a useful sedative in patients with aSAH as it enables neurological assessment during the infusion. The *aim* of this preliminary study was to compare the effects of dexmedetomidine on dynamic and static *cerebral* autoregulation with propofol and/or midazolam in *patients with* aSAH.

Methods: Ten patients were recruited. Dynamic and static *cerebral* autoregulation were assessed *using* transcranial Doppler *ultrasound* during propofol and/or midazolam infusion and then during three increasing doses of dexmedetomidine infusion (0.7, 1.0 and 1.4 $\mu\text{g/kg/h}$). Transient hyperaemic response ratio (THRR) and strength of autoregulation (*SA*) *were calculated to assess dynamic cerebral autoregulation*. *Static rate of autoregulation (sRoR)% was calculated by using noradrenaline infusion to increase the mean arterial pressure 20 mmHg above the baseline.*

Results: *Data from 9 patients were analysed. Compared to baseline, we found no statistically significant changes in THRR or sROR%. THRR was (mean \pm SD) 1.20 \pm 0.14, 1.17 \pm 0.13(p=0.93), 1.14 \pm 0.09 (p=0.72) and 1.19 \pm 0.18 (p=1.0) and sROR% was 150.89 \pm 84.37, 75.22 \pm 27.75 (p=0.08), 128.25 \pm 58.35 (p=0.84) and 104.82 \pm 36.92 (p=0.42) at baseline and during 0.7, 1.0 and 1.4 $\mu\text{g/kg/h}$ dexmedetomidine infusion, respectively. Dynamic SA was significantly reduced after 1.0 $\mu\text{g/kg/h}$ dexmedetomidine (p=0.02).*

Conclusions: Compared to propofol and/or midazolam, dexmedetomidine did not alter static cerebral autoregulation in aSAH patients, whereas a significant change was observed in dynamic SA. Further and larger studies with dexmedetomidine in aSAH patients are warranted.

Editorial Comment:

There may be concern for effects of potent vasodilatory drugs on cerebral vascular tone and responsiveness in patients with intracranial injury. The authors report here that cerebral blood flow autoregulation was unchanged in post- aneurysmal subarachnoid haemorrhage patients who were sedated with dexmedetomidine compared to sedation with midazolam or propofol.

INTRODUCTION

Aneurysmal subarachnoid haemorrhage (aSAH) is a detrimental disease often affecting a relatively young population and leading to severe disability. *Cerebral* autoregulation maintains the cerebral blood flow constant despite changes in mean arterial pressure by changing cerebrovascular resistance. Dynamic and static autoregulation reflect rapid responses to changes in pressure pulsation and slow responses to changes in mean arterial pressure, respectively.¹ Previous studies have *reported that impaired cerebral autoregulation in patients with aSAH predicts the development of radiological vasospasm and delayed cerebral ischemia (DCI); and may correlate with poor outcome.*²⁻⁴

Dexmedetomidine is a selective α_2 -agonist which induces sedation, anxiolysis and analgesia with minimal respiratory depression. *Importantly*, it allows patient awakening *despite* uninterrupted infusion enabling frequent neurological evaluation.⁵ *These properties and potential neuroprotective effects make dexmedetomidine desirable in neurocritical care.*⁶ *While dexmedetomidine seems to attenuate dynamic cerebral autoregulation in healthy volunteers,⁷ its effects on cerebral autoregulation in aSAH patients are unknown. Thus, the primary aim of this preliminary study was to compare dynamic and static cerebral autoregulation in patients with aSAH under dexmedetomidine versus propofol and/or midazolam sedation. We did not aim to study the effect of aSAH on autoregulation per se.*

METHODS

The study was conducted in the Intensive Care Unit in Turku University Hospital, Turku, Finland. The study protocol (EudraCT 2012-000068-11, ClinicalTrials.gov identifier NCT01664520) conformed to the revised Declaration of Helsinki⁸ and was approved by the ethical review board of the Hospital District of Southwest Finland (31/180/2012) and by the Finnish National Agency for Medicines. Written informed consent was obtained from the next of kin.

Patients aged 18-80 years *suffering from aSAH and requiring sedation and mechanical ventilation after aneurysmal treatment (coiling or clipping) were included*. aSAH patients not requiring sedation or mechanical ventilation were excluded. Other exclusion criteria were pregnancy, nursing women, sick sinus syndrome, carotid stenosis, heart rate < 50 beats/min, mean arterial pressure < 55 mmHg, *baseline middle cerebral artery (MCA) flow velocity (V_{MCA}) ≥ 120 cm/s suggesting vasospasm and clinical signs of DCI*.

All patients received intravenous nimodipine infusion and were treated according to Neurocritical Care Society recommendations with local modifications.⁹ ICP was measured continuously using intraparenchymal sensors, either Neurovent-PTO (Raumedic AG, Helmbrechts, Germany) or Codman® ICP Monitoring system (DePuy Synthes, Wokingham, UK). Neurovent-PTO was used in seven patients whereas Codman was used in one patient. *Of the eight patients with intraparenchymal ICP catheter, four patients also had an external ventricular drainage (EVD) due to hydrocephalus*. Two patients had only EVD and in those patients, cerebrospinal fluid was continuously drained and ICP was measured periodically. Cerebral oxygenation was monitored continuously using bilateral near-infrared spectroscopy (NIRS) with INVOS™ cerebral oximetry. In patients with Neurovent-PTO, brain tissue oxygenation (PtiO₂) was *also* monitored. Transcranial Doppler (TCD) was used to measure *bilateral* V_{MCA} using 2 MHz-probes (Atys, Soucieu-en-Jarrest, France) fixed with a head frame.

Study protocol

First, static and dynamic autoregulation were assessed during a constant rate of propofol (2-5 mg/kg/h) and/or midazolam infusion (0.03-0.3 mg/kg/h) (baseline). Thereafter propofol and/or midazolam infusion was stopped and dexmedetomidine (Dexdor® Orion Oyj, Helsinki, Finland) infusion was commenced *at* a dose of 0.7 µg/kg/h according to the total body weight. After two

hours of dexmedetomidine infusion *at constant rate* (in order to reach a steady state), static and dynamic autoregulation were assessed *again*. *While obtaining the steady dexmedetomidine state, all patients received 1-3 mg intravenous doses of oxycodone for analgesia at the discretion of the ICU nurse treating the patient. Next, dexmedetomidine infusion was increased to 1 µg/kg/h for two hours following which, static and dynamic autoregulation were assessed. Finally, dexmedetomidine dose was increased to 1.4 µg/kg/h for another two hours and autoregulation tests were performed once again (see Figure 1). After each period of two hours of dexmedetomidine infusion, arterial blood was sampled to measure the plasma dexmedetomidine concentration (details in supplementary material). During the autoregulation tests, no opioids or other drugs were administered. No blinding was performed. To avoid the effects of temperature, haemoglobin (Hb) and ventilation on cerebral blood flow velocity, these variables were kept constant throughout the study.*

Dynamic autoregulation test

Dynamic autoregulation was assessed with transient hyperaemic response test (THRT) which is *considered safe during the acute phase of SAH.* ¹⁰⁻¹² The common carotid artery was compressed for eight seconds *while the ipsilateral MCA flow velocity (FV) was recorded before and after releasing compression.* Two investigators were always present during the assessment; the compression of carotid artery was performed by the same investigator in all cases (MK) and the FV readings were manually recorded either by RT, MR, JP or AK. The adequacy of compression was assessed visually (a sudden decrease in V_{MCA} with no further decrease). *The test was accepted only when the hemodynamic parameters remained stable during the compression. The intervention was discontinued if there was sinus arrest or if intracranial pressure (ICP) increased above 20 mmHg. When the carotid artery is compressed, a drop in perfusion pressure leads to distal cerebrovascular dilatation as a compensatory mechanism if autoregulatory mechanisms are active. Consequently, after releasing the compression, the V_{MCA} increases beyond the pre-compression value leading to hyperaemic response.* However, in case of impaired autoregulation, no cerebrovascular dilatation or transient hyperaemia will occur.

Transient hyperaemic response ratio (THRR) was calculated as previously described.¹¹

$$THRR = \frac{\text{systolic } FV_{\text{hyperaemia}}}{\text{systolic } FV_{\text{baseline}}}$$

The baseline FV was systolic FV before compression. Due to overshoot phenomenon, the first cardiac cycle was ignored and the systolic FV_{hyperaemia} was the average of the systolic FV of the second and third cardiac cycles after the compression. ¹¹THRR was repeated three times on both hemispheres and there was *at least* 60 seconds interval between the measurements. *The data* was averaged from both hemispheres¹³ and *considered* normal if THRR was ≥ 1.09 and impaired if THRR was < 1.09 . ¹⁰

Strength of dynamic autoregulation (SA) was calculated as

$$SA = \frac{\text{systolic FV}_{\text{hyperaemia}} \cdot \text{MAP of 60 mmHg}}{\text{MAP} \cdot \text{systolic FV}_{\text{baseline}}}$$

where systolic FV_{hyperaemia} is the first flow velocity after the release of carotid compression and MAP of 60 mmHg represents the lower limit of autoregulation. MAP is the mean arterial pressure immediately before the THRT and FV_{baseline} is the flow velocity before carotid compression. ¹⁴ SA value < 1 suggests under regulation and > 1 hyperregulation. ¹⁵ In *the* underregulated situation, cerebral blood vessels are already dilated and a decrease in blood pressure does not result in further dilation, whereas in hyperregulation the cerebral blood vessels dilate more than should be necessary. ¹⁵

Static autoregulation test

Static autoregulation was tested by increasing the mean arterial pressure (MAP) by 20 mmHg with noradrenaline infusion *while* V_{MCA} was continuously monitored with TCD. *After* the MAP had reached the desired level, *the* final V_{MCA} was considered to be mean of the 20 min V_{MCA}. ¹⁶

Measured MAP and FV were used to *calculate estimated* cerebral vascular resistance (CVRe):

$$CVRe = \frac{MAP}{FV}$$

If the percentage change of CVR equals to percentage change in MAP, there would be no change in FV, indicating intact autoregulation.

Static rate of autoregulation (sRoR)% describes the change in cerebrovascular resistance (CVR) determined from the relation between cerebral blood flow velocity (CBFV) and changing cerebral perfusion pressure (CPP). It is calculated:

$$sRoR\% = (\Delta CVR\% / \Delta CPP\%) \times 100, \text{ where } CVR = CPP \div FV$$

However, in those patients who had only EVD, we used MAP (as the CSF was continuously drained) in the formula and sROR% was calculated:

$$sRoR\% = 100 \times \frac{(Initial\ Vmca/Final\ Vmca) - (Initial\ MAP/Final\ MAP)}{1 - (Initial\ MAP/Final\ MAP)}^{17}$$

sRoR of 100% or more indicates that autoregulation is completely intact, meaning that cerebral blood flow velocity is independent of cerebral perfusion pressure. sROR of 0% indicates that cerebral autoregulation is completely *absent*, and cerebral blood flow is linearly related to cerebral perfusion pressure. sROR of 50% is regarded as the cut off for failure of autoregulation.

Accordingly, sRoR indicates quantitatively the stability of changes in cerebral blood flow when arterial blood pressure varies.¹⁸

Statistical analysis

Data is presented as mean± SD. All physiological and TCD parameters including autoregulation indices at various dexmedetomidine doses were compared to their respective baseline values recorded with propofol/midazolam. Power analysis was not performed, and our sample size was based on previous similar autoregulation studies using TCD measurements.¹⁹⁻²¹ The initial aim was to recruit 15 patients, but the recruitment was unexpectedly difficult (due to refusals of next of kin or suspicion of vasospasms in TCD) and very slow (from year 2013 to 2017).

Repeated measures analysis of variance with Dunnett's adjustment for multiple comparisons was used to compare autoregulation indices at various dexmedetomidine doses to their respective baseline values (propofol / midazolam). $P < 0.05$ was considered statistically significant.

Statistical analyses were done using SAS 9.4 System for Windows (SAS Institute Inc., Cary, NC).

RESULTS

Five male and five female patients with mean age of 58.4 ± 10.5 years were recruited. One patient was excluded from dynamic and static autoregulation tests as she had no temporal acoustic window for the TCD, leaving 9 patients for the analysis. The demographic data for the patients is shown in Table 1.

Three patients had no temporal acoustic window on the left side and the Doppler measurements were done only on the right side. One patient expressed profound bradycardia during the dynamic test and was included only in the static test. As a baseline sedation, six patients had propofol infusion, two patients had midazolam infusion, one patient had midazolam infusion combined with propofol infusion and one patient did not have any sedation. The recruitment and the autoregulation tests took place during the first 24-48 hours after the surgical or endovascular treatment. The doses of *oxycodone* given to the patients *between the measurements* were 2.8 ± 1.5 mg after the commencement of *the infusion of dexmedetomidine*, 2.7 ± 1.9 mg after $1.0 \mu\text{g/kg/h}$ and 2.3 ± 1.4 mg after $1.4 \mu\text{g/kg/h}$ dexmedetomidine.

There was no significant difference between the *Hb*, *PaO₂* and *PaCO₂* values at each concentration of dexmedetomidine compared to baseline (Table 2). MAP and CPP were controlled with a *noradrenaline-infusion*.

Overall, the SA was significantly lower after the $1.0 \mu\text{g/kg/h}$ dose of dexmedetomidine compared to baseline (0.75 ± 0.05 , $p=0.02$) No other statistically significant difference was observed in THRR or SA (Figure 2, Table 3) with dexmedetomidine compared with propofol and/or midazolam. There was also no difference in the static parameters V_{MCA} , CVR, sROR% (Figure 3) and PI (Figure 4) with dexmedetomidine compared with propofol and/or midazolam (Table 4).

One patient had impaired dynamic autoregulation at baseline, and it did not change with the administration of dexmedetomidine. This patient had impaired THRR values bilaterally. One patient had an impaired dynamic autoregulation on THRT after the initial dose of dexmedetomidine, but not after higher doses. One patient had $\text{THRR} < 1.08$ after the initial and the $1.0 \mu\text{g/kg/h}$ dose, but not after the highest dose, and one other patient showed an impaired dynamic autoregulation after the two highest doses. SA values were < 1 in all patients, and there was a statistically significant reduction in SA after the $1.0 \mu\text{g/kg/h}$ dose compared to baseline ($p=0.02$).

The patient, who had *impaired* dynamic autoregulation *at baseline also* had sROR% values < 50% throughout the *study* indicating *impaired static* autoregulation. Three other patients had sROR% < 50% at some point during the *study*.

There was no difference in *cerebral* oxygenation (PtiO₂ and NIRS, Table 4) between baseline and different doses of dexmedetomidine.

Figure 5 *shows* a Bland-Altman plot to compare the agreement of the sROR% measurements using MAP or CPP.

We performed a subgroup analysis of the data for the five patients who had TCD measurements from both sides. We found no statistical differences in the autoregulation indices at any dexmedetomidine dose compared to baseline (data not shown).

The cumulative dose of propofol before the commencement of dexmedetomidine was 6004±4165 mg (N=7) and that of midazolam was 125.7±79 mg (N=3). *The mean dexmedetomidine concentrations were 0.7± 0.22 ng/ml (after 0.7 µg/kg/h for 2 hours), 1.19± 0.35 ng/ml (after 1.0 µg/kg/h for 2 hours) and 1.69± 0.39 ng/ml (after 1.4 µg/kg/h for 2 hours).* There was a trend towards a lower *noradrenaline* requirement with increasing dose of dexmedetomidine, but we found no statistically significant difference between the noradrenaline doses.

DISCUSSION

In this preliminary study *where each patient with aSAH served as their own control*, dexmedetomidine did not change static cerebral autoregulation indices compared to propofol and/or midazolam. SA was significantly lower after 1.0 µg/kg/h dose of dexmedetomidine when compared to propofol and/or midazolam, although there were no significant changes in other dynamic autoregulation indices even with higher doses.

Cerebral autoregulation is often impaired in the first days after aSAH¹⁹ and is associated with poor outcome.^{3,4,20} Previous studies have primarily concentrated on the dynamic component of cerebral autoregulation in aSAH patients. *To the best of our knowledge, only one study has evaluated static autoregulation in aSAH and found that it was not impaired.*²¹ *No previous studies have evaluated both elements of autoregulation in aSAH patients. We decided to test both dynamic and static cerebral autoregulation because they may be differently affected. For example, in ischemic stroke patients, while dynamic autoregulation is impaired for several days during the acute phase, static autoregulation remains unaffected.*^{22,23} *Moreover, some anaesthetic agents impair dynamic but not static cerebral autoregulation.*^{24,25}

There are multiple methods for investigating cerebral autoregulation. *These include examining the recovery of CBFV after a rapid decrease of arterial blood pressure by using thigh cuff test*^{26,27,28} *and examining spontaneous fluctuations in CBFV in relationship with MAP, ICP and brain tissue oxygenation (Cambridge Enterprise Ltd, University of Cambridge, UK).*²⁹ *We used the THRT for assessing dynamic autoregulation because it allows brief period of reduction in CBFV and is deemed safe in aSAH. Furthermore, we calculated SA, which is not affected by hemodynamic factors.*¹⁵ *Studying static cerebral autoregulation is traditionally performed by increasing MAP with a vasopressor and simultaneously measuring MAP and MCA flow velocities.*²⁷ *Modern techniques use PET scanning, which images CBF.*³⁰ *However, we preferred TCD to be able to perform the testing on the patient's bedside and to avoid the need to transport intubated and sedated patients for imaging.*

In healthy, anaesthetised patients, there is a correlation *between* both dynamic autoregulation tests (thigh cuff test, THRT and dynamic strength of autoregulation) and static autoregulation when static rate of autoregulation is used.^{27,31} *However, various methods are probably not interchangeable*^{32,33} *and there is no general consensus on how autoregulation should be monitored.*

Dynamic autoregulation has previously been shown to be impaired in healthy volunteers after administration of dexmedetomidine.⁷ In this study, we found that the SA was significantly lower after the 1.0 µg/kg/h dose of dexmedetomidine compared to baseline, but not after the initial 0.7 µg/kg/h or the highest dose 1.4 µg/kg/h. It is possible that the effect of dexmedetomidine on dynamic autoregulation may be dose dependent in this population. Also, the ICP was not elevated in our patients and hence, they may have been less susceptible to any autoregulatory impairment with dexmedetomidine. Elevated ICP is known to correlate with impaired cerebral autoregulation.³⁴ In previous volunteer studies, dexmedetomidine administration was associated with decrease in MAP, cardiac output and CBF.^{7,35} In contrast, we kept the blood pressure constant during dexmedetomidine infusion and THRT which may explain to some extent why there were no changes in most of the autoregulation indices. Dexmedetomidine induced reduction in CBF has been shown to be less in patients with traumatic brain injury if blood pressure is maintained at the pre-sedation level.³⁶ We used noradrenaline infusion in maintaining and increasing MAP and CPP levels.³⁷ Consequently, it is possible that autoregulatory impairment was not detected. It is possible that autoregulation was intact within the blood pressure range studied but may have been impaired outside of that range.

During the first days after aSAH, many patients have low CBF regardless of vasospasm or DCI.³⁸ The global CBF in patients with Fisher grade 4 aSAH is lower than patients with Fisher grade 3, the impact of Fisher grade on CBF being more profound than the Hunt & Hess grades.³⁸ Since 8 of our 10 patients had Fisher grade 4 aSAH, it is unlikely that the heterogeneity of Hunt & Hess grades had an effect on our findings.

Our study has important limitations. Firstly, the sample size is small and larger studies are needed to confirm our preliminary findings. Secondly, the baseline sedation was not the same in all the patients. While most patients had propofol-infusion, two had midazolam-infusion, one had both and one had no sedation. The patients were continuously sedated for a few days before administration of dexmedetomidine which can confound autoregulation status. Ogawa et al found that midazolam seems to improve whereas propofol seems to have no effect on dynamic cerebral autoregulation in healthy volunteers.³⁹ In patients with traumatic brain injury, large, doses of propofol (more than 4 mg/kg/h) have been shown to impair static autoregulation.³⁰ We discontinued propofol 2 hours before the first and almost 6.5 hours before the last autoregulation assessments. After >12 hours of infusion of propofol, it takes 3.5 hours to reduce the plasma

concentration to 20%.⁴⁰ Therefore, the likelihood of residual propofol affecting cerebral autoregulation is small. Midazolam, on the other hand, may have had an effect on the dynamic autoregulation in our patients but only 3 patients were administered midazolam. Next, TCD only provides an estimate of CBF and it is assumed that the diameter of basal cerebral arteries varies only minimally with changes in MAP.^{41 42} This presumption has been recently challenged and TCD observations should be carefully interpreted for CBF.⁴³ Fourth, we performed the study during the first days after aSAH, before the DCI usually appears and it is possible that autoregulatory status may change over time.

In conclusion, our preliminary findings indicate that in patients with aSAH, there was no difference in static cerebral autoregulation between dexmedetomidine and propofol and/or midazolam. The dynamic SA values, however, were significantly lower after 1.0 µg/kg/h dose of dexmedetomidine when compared to propofol and/or midazolam. This finding suggests that a sudden decrease in arterial blood pressure in aSAH patients during dexmedetomidine sedation may not be desirable. These findings warrant further studies with larger sample size.

ACKNOWLEDGEMENTS

We would like to thank Mikko Kuoppamäki and Peter Makary from Orion Corporation for providing the analysis of dexmedetomidine concentrations. We would also like to thank the nursing staff at the Intensive Care Unit in Turku University Hospital for collaboration and patience during the study.

Supplemental Content (Method description for measuring the dexmedetomidine plasma concentration and a table showing the actual measured concentrations of dexmedetomidine (ng/ml) in each patient)

Table 1.

Demographics of the patients.

Table 2.

PaCO₂ PaO₂ and Haemoglobin (Mean ± SD) at baseline and at different doses of dexmedetomidine. There were no statistically significant changes at different doses of *dexmedetomidine* compared to baseline.

Table 3.

The indices for dynamic cerebral autoregulation at baseline (Propofol and/or Midazolam) and at different *doses* of dexmedetomidine (*Dex*).

Table 4.

The indices for static cerebral autoregulation at baseline (Propofol and/or Midazolam) and at different *doses* of dexmedetomidine (*Dex*); initial states the baseline values before the augmentation of MAP and final states the values during increased MAP. The results during each *dose* of dexmedetomidine (*Dex*) were compared to baseline. PI, sROR% and V_{MCA} are reported as an averaged value for both sides. The table also shows the brain tissue oxygenation, PtiO₂, and near infrared spectroscopy (NIRS) values during baseline and each dose of dexmedetomidine. The NIRS values are mean values of both sides. No significant difference was seen between the doses.

Figure 1.

Study protocol.

Figure 2.

Boxplot for dynamic autoregulation indices, THRR and SA, at baseline (propofol/midazolam) and at each *dose* of dexmedetomidine. Boxes represent lower quartiles, medians and upper quartiles, whiskers represent 1.5 x inter-quartile ranges below and above the lower and upper quartiles, respectively. Outlying values are marked with a symbol.

Figure 3.

Boxplots for static rate of autoregulation, sROR%, calculated using MAP or CPP at baseline (propofol/midazolam) and at each *dose* of dexmedetomidine. Boxes represent lower quartiles, medians and upper quartiles, whiskers represent 1.5 x inter-quartile ranges below and above the lower and upper quartiles, respectively.

Figure 4.

Individual values for pulsatility index, PI, at baseline (propofol/midazolam) and at each *dose* of dexmedetomidine.

Figure 5.

A Bland-Altman plot to compare the agreement of the sROR% measurements using MAP or CPP.

REFERENCES

1. Rasulo FA, Balestreri M, Matta B. Assessment of cerebral pressure autoregulation. *Current Opinion in Anaesthesiology* 2002; 15: 483–8.
2. Fontana J, Moratin J, Ehrlich G, Scharf J, Weiß C, Schmieder K, Barth M. Dynamic Autoregulatory Response After Aneurysmal Subarachnoid Hemorrhage and Its Relation to Angiographic Vasospasm and Clinical Outcome. *Neurocrit Care* 2015; 23: 355–63.
3. Rynkowski CB, de Oliveira Manoel AL, Reis dos MM, Puppo C, Worm PV, Zambonin D, Bianchin MM. Early Transcranial Doppler Evaluation of Cerebral Autoregulation Independently Predicts Functional Outcome After Aneurysmal Subarachnoid Hemorrhage. *Neurocrit Care* 2019; 31: 253–62.
4. Budohoski KP, Czosnyka M, Smielewski P, Kasprowicz M, Helmy A, Bulters D, Pickard JD, Kirkpatrick PJ. Impairment of cerebral autoregulation predicts delayed cerebral ischemia after subarachnoid hemorrhage: a prospective observational study. *Stroke* 2012; 43: 3230–7.
5. Keating GM. Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting. *Drugs* 2015; 75: 1119–30.
6. Farag E, Argalious M, Sessler DI, Kurz A, Ebrahim ZY, Schubert A. Use of $\alpha(2)$ -Agonists in Neuroanesthesia: An Overview. *Ochsner J* 2011; 11: 57–69.
7. Ogawa Y, Iwasaki K-I, Aoki K, Kojima W, Kato J, Ogawa S. Dexmedetomidine weakens dynamic cerebral autoregulation as assessed by transfer function analysis and the thigh cuff method. *Anesthesiology* 2008; 109: 642–50.
8. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA* 2013; 310: 2191–4.
9. Diring MN, Bleck TP, Claude Hemphill J, Menon D, Shutter L, Vespa P, Bruder N, Connolly ES, Citerio G, Gress D, Hänggi D, Hoh BL, Lanzino G, Le Roux P, Rabinstein A, Schmutzhard E, Stocchetti N, Suarez JJ, Treggiari M, Tseng M-Y, Vergouwen MDI, Wolf S, Zipfel G, Neurocritical Care Society. Critical care management of patients following

aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. 2011. pages 211–40.

10. Lam JM, Smielewski P, Czosnyka M, Pickard JD, Kirkpatrick PJ. Predicting delayed ischemic deficits after aneurysmal subarachnoid hemorrhage using a transient hyperemic response test of cerebral autoregulation. *Neurosurgery* 2000; 47: 819–25.
11. Rätsep T, Asser T. Cerebral hemodynamic impairment after aneurysmal subarachnoid hemorrhage as evaluated using transcranial doppler ultrasonography: relationship to delayed cerebral ischemia and clinical outcome. *J Neurosurg* 2001; 95: 393–401.
12. Smielewski P, Czosnyka M, Kirkpatrick P, Pickard JD. Evaluation of the transient hyperemic response test in head-injured patients. *J Neurosurg* 1997; 86: 773–8.
13. Steiner LA, Coles JP, Johnston AJ, Chatfield DA, Smielewski P, Fryer TD, Aigbirhio FI, Clark JC, Pickard JD, Menon DK, Czosnyka M. Assessment of cerebrovascular autoregulation in head-injured patients: a validation study. *Stroke* 2003; 34: 2404–9.
14. Harrison JM, Girling KJ, Mahajan RP. Effects of target-controlled infusion of propofol on the transient hyperaemic response and carbon dioxide reactivity in the middle cerebral artery. *BJA: British Journal of Anaesthesia* 1999; 83: 839–44.
15. Mahajan RP, Cavill G, Simpson EJ. Reliability of the Transient Hyperemic Response Test in Detecting Changes in Cerebral Autoregulation Induced by the Graded Variations in End-Tidal Carbon Dioxide. *Anesthesia & Analgesia* 1998; 87: 843–9.
16. Steiner LA, Johnston AJ, Chatfield DA, Czosnyka M, Coleman MR, Coles JP, Gupta AK, Pickard JD, Menon DK. The effects of large-dose propofol on cerebrovascular pressure autoregulation in head-injured patients. *Anesthesia & Analgesia* 2003; 97: 572–6.
17. Strebel S, Lam AM, Matta B, Mayberg TS, Aaslid R, Newell DW. Dynamic and static cerebral autoregulation during isoflurane, desflurane, and propofol anesthesia. *Anesthesiology* 1995; 83: 66–76.
18. Lang EW. Continuous monitoring of cerebrovascular autoregulation: a validation study. *Journal of Neurology, Neurosurgery & Psychiatry* 2002; 72: 583–6.

- Accepted Article
19. Otite F, Mink S, Tan CO, Puri A, Zamani AA, Mehregan A, Chou S, Orzell S, Purkayastha S, Du R, Sorond FA. Impaired cerebral autoregulation is associated with vasospasm and delayed cerebral ischemia in subarachnoid hemorrhage. *Stroke* 2014; 45: 677–82.
 20. Jaeger M, Soehle M, Schuhmann MU, Meixensberger J. Clinical significance of impaired cerebrovascular autoregulation after severe aneurysmal subarachnoid hemorrhage. *Stroke* 2012; 43: 2097–101.
 21. Diringer MN, Dhar R, Scalfani M, Zazulia AR, Chicoine M, Powers WJ, Derdeyn CP. Effect of High-Dose Simvastatin on Cerebral Blood Flow and Static Autoregulation in Subarachnoid Hemorrhage. *Neurocrit Care* 2016; 25: 56–63.
 22. Dawson SL, Blake MJ, Panerai RB, Potter JF. Dynamic but not static cerebral autoregulation is impaired in acute ischaemic stroke. *Cerebrovasc Dis* 2000; 10: 126–32.
 23. Dawson SL, Panerai RB, Potter JF. Serial changes in static and dynamic cerebral autoregulation after acute ischaemic stroke. *Cerebrovasc Dis* 2003; 16: 69–75.
 24. Ogawa Y, Iwasaki K-I, Shibata S, Kato J, Ogawa S, Oi Y. The effect of sevoflurane on dynamic cerebral blood flow autoregulation assessed by spectral and transfer function analysis. *Anesthesia & Analgesia* 2006; 102: 552–9.
 25. Gupta S, Heath K, Matta BF. Effect of incremental doses of sevoflurane on cerebral pressure autoregulation in humans. *BJA: British Journal of Anaesthesia* 1997; 79: 469–72.
 26. Aaslid R, Lindegaard KF, Sorteberg W, Nornes H. Cerebral autoregulation dynamics in humans. *Stroke* 1989; 20: 45–52.
 27. Tiecks FP, Lam AM, Aaslid R, Newell DW. Comparison of static and dynamic cerebral autoregulation measurements. *Stroke* 1995; 26: 1014–9.
 28. Vavilala MS, Newell DW, Junger E, Douville CM, Aaslid R, Rivara FP, Lam AM. Dynamic cerebral autoregulation in healthy adolescents. *Acta Anaesthesiol Scand* 2002; 46: 393–7.

29. Czosnyka M, Brady K, Reinhard M, Smielewski P, Steiner LA. Monitoring of cerebrovascular autoregulation: facts, myths, and missing links. *Neurocrit Care* 2009; 10: 373–86.
30. Steiner LA, Coles JP, Johnston AJ, Chatfield DA, Smielewski P, Fryer TD, Aigbirhio FI, Clark JC, Pickard JD, Menon DK, Czosnyka M. Assessment of Cerebrovascular Autoregulation in Head-Injured Patients. *Stroke* 2003; 34: 2404–9.
31. Tibble RK, Girling KJ, Mahajan RP. A comparison of the transient hyperemic response test and the static autoregulation test to assess graded impairment in cerebral autoregulation during propofol, desflurane, and nitrous oxide anesthesia. *Anesthesia & Analgesia* 2001; 93: 171–6.
32. Budohoski KP, Zweifel C, Kaspruwicz M, Sorrentino E, Diedler J, Brady KM, Smielewski P, Menon DK, Pickard JD, Kirkpatrick PJ, Czosnyka M. What comes first? The dynamics of cerebral oxygenation and blood flow in response to changes in arterial pressure and intracranial pressure after head injury. *British Journal of Anaesthesia* 2012; 108: 89–99.
33. Budohoski KP, Czosnyka M, Smielewski P, Varsos GV, Kaspruwicz M, Brady KM, Pickard JD, Kirkpatrick PJ. Cerebral autoregulation after subarachnoid hemorrhage: comparison of three methods. *J Cereb Blood Flow Metab* 2013; 33: 449–56.
34. de-Lima-Oliveira M, Salinet ASM, Nogueira RC, de Azevedo DS, Paiva WS, Teixeira MJ, Bor-Seng-Shu E. Intracranial Hypertension and Cerebral Autoregulation: A Systematic Review and Meta-Analysis. *World Neurosurgery* 2018; 113: 110–24.
35. Prielipp RC, Wall MH, Tobin JR, Groban L, Cannon MA, Fahey FH, Gage HD, Stump DA, James RL, Bennett J, Butterworth J. Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow. *Anesthesia & Analgesia* 2002; 95: 1052–9.
36. Wang X, Ji J, Fen L, Wang A. Effects of dexmedetomidine on cerebral blood flow in critically ill patients with or without traumatic brain injury: a prospective controlled trial. *Brain Inj* 2013; 27: 1617–22.

- Accepted Article
37. Steiner LA, Johnston AJ, Czosnyka M, Chatfield DA, Salvador R, Coles JP, Gupta AK, Pickard JD, Menon DK. Direct comparison of cerebrovascular effects of norepinephrine and dopamine in head-injured patients. *Crit Care Med* 2004; 32: 1049–54.
 38. Engquist H, Lewén A, Howells T, Johnson U, Ronne-Engström E, Nilsson P, Enblad P, Rostami E. Hemodynamic Disturbances in the Early Phase After Subarachnoid Hemorrhage: Regional Cerebral Blood Flow Studied by Bedside Xenon-enhanced CT. *J Neurosurg Anesthesiol* 2018; 30: 49–58.
 39. Ogawa Y, Iwasaki K-I, Aoki K, Gokan D, Hirose N, Kato J, Ogawa S. The different effects of midazolam and propofol sedation on dynamic cerebral autoregulation. *Anesthesia & Analgesia* 2010; 111: 1279–84.
 40. Sahinovic MM, Struys MMRF, Absalom AR. Clinical Pharmacokinetics and Pharmacodynamics of Propofol. *Clin Pharmacokinet* 2018; 57: 1539–58.
 41. Naqvi J, Yap KH, Ahmad G, Ghosh J. Transcranial Doppler Ultrasound: A Review of the Physical Principles and Major Applications in Critical Care. *International Journal of Vascular Medicine* 2013; 2013: 1–13.
 42. Giller CA, Bowman G, Dyer H, Mootz L, Krippner W. Cerebral arterial diameters during changes in blood pressure and carbon dioxide during craniotomy. *Neurosurgery* 1993; 32: 737–41.
 43. Verbree J, Bronzwaer A, van Buchem MA, Daemen M, van Lieshout JJ, van Osch M. Middle cerebral artery diameter changes during rhythmic handgrip exercise in humans. *J Cereb Blood Flow Metab* 2017; 37: 2921–7.

FUNDING

This study was partially funded by Government's Special Financial Transfer tied to academic research in Health Sciences (Finland) no 13132 (R. Takala), no 13821 (T. Saari) and no 11043 (M. Kallioinen).

Dr. Posti has received funding from Academy of Finland (#17379) and Government's Special Financial Transfer tied to academic research in Health Sciences (Finland). Dr. Posti has also received a grant from Maire Taponen Foundation.

CONFLICTS OF INTEREST

Dr. Takala is a minor stock owner of Orion Corporation and Oriola. Dr. Takala has received speaker's fee from Orion Corporation, Abbott, Baxter, Fresenius Kabi and UCB and travel grants from Steripolar and Pfizer.

Dr. Posti has received speaker's fees from Orion Corporation and Finnish Medical Association and a travel grant from Stryker Corporation.

Dr. Grönlund has received speaker's fees from Orion Corporation.

Dr. Saari has received speaker's fees from Orion Corporation.

Dr. Frantzén has received speaker's fees from Orion Corporation and Teva Pharmaceutical Industries and a travel grant from Abbot.

Table 1. Demographics of the patients that were included in the analysis. Data is presented as mean +/- SD.

Age (yr.)	58.1 ± 11.1
Height (cm)	173.4 ± 8.2
Weight (kg)	74.8 ± 11.4
Sex (male/female)	5 / 4
GCS at admission (grade)	(n)
15	1
13	1
12	2
9	1
6	1
5	1
3	2
Hunt & Hess (grade)	(n)
3	4
4	4
5	1
Fisher (grade)	(n)
3	2
4	7
Aneurysm	(n)
ICA (dx/sin)	3 (2/0)
MCA (dx/sin)	4 (2/2)
ACA	3
Treatment	(n)

Coiling	7
Coiling and stenting	0
Clipping	2
Study performed days after rupture	(n)
2	3
3	3
4	2
5	1
Smoking (yes/no/not known)	4/4/1
Hypertension (yes/no)	2/7
Diabetes (yes/no)	0/9
*The one excluded patient was female, 61 years old, had GCS 6 at admission, Fisher 4, Hunt&Hess 4, had ICA l.sin aneurysm that was treated with coils and stent three days after rupture,, she was a smoker and had diabetes and hypertension	

Table 2. PaCO₂ PaO₂ and Haemoglobin (Mean \pm SD) at baseline and at different doses of dexmedetomidine (Dex). There were no statistically significant changes at different dexmedetomidine doses compared to baseline.

	Propofol	Dex 0.7	p-value	Dex 1.0	p-value	Dex 1.4	p-value
PaCO ₂ (mmHg)	37.3 \pm 2.3	36.2 \pm 2.6	0.62	35.4 \pm 2.5	0.21	35.0 \pm 2.3	0.10
PaO ₂ (mmHg)	132.4 \pm 37.3	149.7 \pm 57.7	0.82	152.7 \pm 59.1	0.75	151.1 \pm 62.2	0.79
Hb (g/l)	124 \pm 16	127 \pm 15	0.92	128 \pm 14	0.88	129 \pm 14	0.79

Table 3. The indices for dynamic cerebral autoregulation at baseline (Propofol and/or Midazolam) and at different doses of dexmedetomidine (Dex). THRR = transient hyperemic response ratio, SA = strength of autoregulation.


	Baseline	Dex 0.7	p-value	Dex 1.0	p-value	Dex 1.4	p-value
THRR both	1.20 ±0.14	1.17±0.13	0.93	1.14±0.09	0.72	1.19±0.18	1.0
SA both	0.89±0.13	0.80±0.12	0.15	0.75±0.05	0.02	0.78±0.08	0.07


Table 4. The indices for static cerebral autoregulation at baseline (Propofol and/or Midazolam) and at different doses of dexmedetomidine (Dex); initial states the baseline values before the augmentation of MAP and final states the values during increased MAP. The results during each dose of dexmedetomidine were compared to baseline. PI, sROR% and V_{MCA} are reported as an averaged value for both sides. The table also shows the brain tissue oxygenation, $PtiO_2$, and near infrared spectroscopy (NIRS) values during baseline and each dose of dexmedetomidine. The NIRS values are mean values of both sides. No significant difference was seen between the doses. MAP=mean arterial pressure; CPP = cerebral perfusion pressure; ICP = intracranial pressure; CVR=cerebrovascular resistance; sROR=static rate of autoregulation; PI=pulsatility index; V_{MCA} =velocity of the blood flow the middle cerebral artery; $PtiO_2$ = brain tissue oxygenation; NIRS = near infrared spectroscopy.


	Baseline	Dex 0.7	p-value	Dex 1.0	p-value	Dex 1.4	p-value
MAP mmHg initial	80.70±10.51	87.50±9.0	0.22	88.90±7.99	0.11	89.10±7.72	0.10
MAP mmHg final	98.40±11.08	104.80±10.00	0.38	109.50±10.05	0.05	109.00±9.88	0.07
ΔMAP%	21.70±5.12	20.60±4.11	0.90	23.10±4.18	0.81	22.30±3.80	0.98
CPP mmHg initial	78.68±6.77	79.80±8.92	0.99	80.91±9.16	0.91	82.39±8.41	0.71
CPP mmHg final	91.15±6.79	97.23±9.11	0.34	100.53±7.38	0.08	101.15±9.37	0.06
ΔCPP mmHg	16.09±7.22	22.11±4.71	0.22	24.86±8.55	0.47	23.04±6.88	0.14
ICP mmHg initial	8.93±5.88	9.60±4.77	0.99	9.28±5.00	1.00	9.70±4.84	0.98
ICP mmHg final	9.55±6.18	9.56±4.85	1.00	8.84±4.90	0.99	9.88±5.50	1.00
ΔCVR%	22.66±14.26	15.02±7.18	0.41	22.26±11.52	0.99	19.09±13.39	0.86
sROR% (CPP)	150.89±84.37	75.22±27.75	0.08	128.25±58.35	0.84	104.82±36.92	0.42
sROR% (MAP)	110.01±77.97	80.45±33.63	0.55	91.78±35.23	0.82	89.79±54.82	0.77
PI	1.37±0.39	1.41±0.32	0.99	1.46±0.45	0.92	1.43±0.36	0.98


VMCA cm/s initial	67.50±24.50	64.67±21.38	0.98	60.28±18.57	0.81	60.33±19.40	0.82
VMCA cm/s final	66.63±22.17	68.33±22.72	1.00	61.00±17.94	0.90	62.67±22.43	0.96
PtiO ₂ mmHg initial	24.9±14.8	22.7±18.5	0.99	22.5±18.3	0.99	22.9±17.7	0.99
PtiO ₂ mmHg final	24.9±16	24.3±18.9	1.0	23.7±19.3	1.0	24.6±18.6	1.0
NIRS % initial mean	71.5±10.4	72±11	1.0	69.7±11.5	0.97	69.5±10.5	0.96
NIRS % final mean	72.3±9.7	72.6±10.8	1.0	71.3±11.2	0.99	70.8±10.7	0.98

Figure 1. Study protocol.











CVR difference (MAP vs CPP based)



sROR% (MAP vs CPP based)



based on data from ~/Data static final corrected.xlsx